focus -WSS

focus

author：Wikipedia 2025-09-28 13:25:55 - browse：1866

Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from Covid-19 vaccines are flowing behind the scenes, going to the contract manufacturers and clinical-trial organizers that turn the shots from lab-bench theory to mass-produced reality.

Both AstraZeneca and Johnson & Johnson publicly committed to not profiting off their products during the pandemic — though AstraZeneca has reserved the right to declare the pandemic over on July 1, even if the World Health Organization has not. Pfizer and Moderna made no such pledge, with Pfizer expected to make $15 billion in vaccine-related revenue this year, while Moderna is forecasting $18.4 billion in vaccine sales.

Contractors hired to test and manufacture these vaccines have enjoyed a share of the profits without the same level of public scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Eli Lilly’s Mounjaro succeeds in second weight

WSS

Latigo launches with $135 million for Vertex

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Biden administration plans revamp of organ transplant system

Tome Biosciences co

Millions may soon lose Medicaid when they don't have to

Novo: Oral version of Ozempic leads to 15% weight loss

entertainment

focus

explore

The high cost of giving birth even with insurance

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Walensky prepares to leave CDC — and Congress — behind

A public health expert passes on football's full body collisions for youths

DIEP, the 'gold standard' of breast reconstruction, is under threat

Xenotransplantation trials will require adjusting expectations, experts say

New air purifier tech could be key to improving indoor air quality

Artificial intelligence use in health care faces greater scrutiny in 2024

Jerome Adams on the need for new antivirals for Covid

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

explore

Xenotransplantation trials will require adjusting expectations, experts say

Biogen nominates mother of director’s child to replace him on board

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

The thinking behind the controversial eating disorder chatbot Tessa

A public health expert passes on football's full body collisions for youths

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

leisure time

knowledge

leisure time

hotspot